Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2004

View Archived Issues

Histone deacetylase inhibitor effective against esophageal carcinoma in vitro

Genzyme to buy back certain Synvisc rights from Wyeth

Novel macrolides effective against multiresistant strains of pneumococci and H. influenzae

New approval for Eloxatin

Phenoxodiol receives fast track status for recurrent ovarian cancer

Ferrer to distribute Barrier's products

Treatment of multifactor anemia by hypoxia-inducible factor inhibitor

Phase II trials in Canada, E.U. evaluate AMD-3100 for stem cell transplantation

Dynogen acquires pumosetrag from Mitsubishi Pharma

Norditropin approved for adults with severe growth hormone deficiency

CytoGenix submits pre-IND brief for antiherpes drug CY-301

Add-on therapy with Reverset reduces viral load in HIV-infected patients

GX-015-070 enters phase I

Inspire licenses novel glaucoma technology

AstraZeneca to resubmit Symbicort Single Inhaler Therapy file in E.U.

Marqibo submitted for marketing approval in Canada

Phase II data support 873140 as an antiviral for HIV infection

Affimed Therapeutics and Syngenta to codevelop Tandab antibody

Results of PROTECT trial of Integrilin

New data on the benefits of Ampligen in chronic fatigue syndrome

Rifalazil shows promise in the treatment of Chlamydia infections

New data on the pharmacokinetics and tolerability of the neuromuscular blocker AV-430A

Long-term benefits of ranibizumab in neovascular AMD patients

Improved visual acuity found with ruboxistaurin in DME involving the center of macula

New PPARgamma activators and their use in type 2 diabetes and metabolic syndrome

Indian researchers isolate new cytotoxic terpenes from plants

New chiral antiarrhythmic agent covered by Aventis patent

ARS scientists prepare and test novel amylin antiaggregatory peptides

New cathepsin S inhibitors in early development at Boehringer Ingelheim

New elastase release inhibitors described by Taisho and U. of Texas scientists

Adolor claims novel opioid antagonists for use in GI disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...